Jonathan Rubin, MD, MBA, chief medical officer at Supernus Pharmaceuticals, talked about the recent approval of the company’s subcutaneous infusion therapy SPN-830 for Parkinson disease.
Jonathan Rubin, MD, MBA
Advertisement
Chief medical officer and senior vice president of Research & Development at Supernus Pharmaceuticals.
Articles by Jonathan Rubin, MD, MBA
Advertisement
Latest Updated Articles
Insights on the Newly Approved Subcutaneous Infusion Therapy for Parkinson DiseasePublished: February 6th 2025 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Alexander Gold, MD, on Adrabetadex’s Impact in Infantile-Onset Niemann-Pick C
2
NeurologyLive® Brain Games: November 2, 2025
3
Designing the Phase 3 EMPEROR Trial and Future Considerations
4
Efgartigimod Effective in Seronegative gMG, Obexelimab Meets Primary End Point, FDA Accepts NDA for Tau Tracer MK-6240
5
